NCT07645287
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 55 → 59 locations
Notable Eligibility criteria expanded, about 7 words Show 4 more changesShow less
- Primary endpoints: details revised at 2 of 2 entries
- Study sites: 55 to 57
- Interventions: B/F/TAF (Drug), GS-3242 Injection (Drug), GS-3242 Tablet (Drug), Lenacapavir Injection (Drug), Lenacapavir Tablet (Drug) to B/F/TAF (Drug), GS-3242 Injection (Drug), GS-3242 Tablet (Drug), Lenacapavir Injection (Drug), Lenacapavir Tablet (Drug)
- Secondary endpoints: details revised at 4 of 14 entries
- Minor Trial sites expanded: 36 → 55 locationsv4
- Minor Trial sites expanded: 3 → 36 locationsv3
- Notable Recruitment opened
- Trial sites expanded: 0 → 3 locations
- Start date changed from estimate of Jun 2026 to Jun 15, 2026
- Secondary endpoints revised (14)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (14)
Show 9 moreShow less
Arms and interventions
Participants will be randomized to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed by intramuscular (IM) injections of GS-3242 and LEN up to 52 weeks.
Participants will be randomized to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed by a IM injections of GS-3242 (at a different dose than Group 1) and LEN up to 52 weeks.
Participants will be randomized to continue to receive 50/200/25 mg of B/F/TAF daily for up to 52 weeks.
Participants will be enrolled (non-randomized) to receive oral loading doses of GS-3242 in combination with LEN oral tablets, followed IM injection of GS-3242 and LEN (at different doses than Groups 1 and 2) up to 52 weeks.
Drugs: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF
Sites
59 sites in 4 countries
United States 49, Australia 4, Canada 3, Puerto Rico 3